8-K: Dianthus Therapeutics Announces Board Changes: Kiselak Resigns, Kango Appointed

Dianthus Therapeutics reports the resignation of Tomas Kiselak from the Board of Directors and the appointment of Sujay Kango as a new Class II director and Compensation Committee member, effective March 4, 2025.

Summary

• On March 4, 2025, Tomas Kiselak resigned from the Board of Directors of Dianthus Therapeutics, Inc.
• The resignation was not due to any disagreements with the company's operations, policies, or practices.
• On the same day, Sujay Kango was appointed as a Class II director and a member of the Compensation Committee.
• Kango will receive an initial option grant to purchase 25,000 shares of Dianthus Therapeutics' common stock, vesting over three years.
• He will also receive $40,000 per year for his service on the Board and $6,000 per year for his service on the Compensation Committee, payable quarterly.
• Kango will be eligible for annual equity awards and will enter into a standard indemnification agreement.

Sentiment

Score: 7

Explanation: The announcement is neutral, reflecting standard corporate governance procedures. The changes are not indicative of any underlying issues or strategic shifts.

Positives

• The appointment of Sujay Kango adds a new member to the Board and Compensation Committee.
• The equity grant and compensation package for Kango are in line with the company's Non-Employee Director Compensation Policy.

Future Outlook

The company will continue to operate under its current Non-Employee Director Compensation Policy, with annual equity awards granted to directors.

Industry Context

Changes in board composition are a normal part of corporate governance, reflecting the evolving needs and priorities of the company.

Management Changes

Stakeholder Impact

• Shareholders may view the board changes as part of the company's ongoing governance and strategic development.
• The new director will be compensated according to the company's existing policy.

Key Dates